Here is a breakdown of Ajanta Pharma Limited (AJANTPHARM), covering its financial performance and how the market is currently valuing the stock.
Ajanta Pharma Revenue Trend
Revenue for Ajanta Pharma Limited came in at ₹5,625 Cr in FY2026, an 18.6% increase from ₹4,743 Cr in FY2025.
Sustaining a 12.5% CAGR over 10 years places Ajanta Pharma Limited in solid growth territory. Revenue expanded from ₹1,728 Cr to ₹5,625 Cr across that decade.
At ₹5,625 Cr in annual revenue, Ajanta Pharma Limited occupies a mid-sized position within the Indian pharmaceuticals sector.
With 7 straight years of revenue growth behind it, this reads as a durable trend rather than a one-time uptick for Ajanta Pharma Limited.
| Year | Revenue | YoY % |
|---|---|---|
| FY2026 | ₹5,625 Cr | +18.6% |
| FY2025 | ₹4,743 Cr | +10.5% |
| FY2024 | ₹4,293 Cr | +11.8% |
| FY2023 | ₹3,841 Cr | +11.1% |
| FY2022 | ₹3,457 Cr | — |
View Ajanta Pharma Limited's full 10-year revenue trend with CAGR analysis →
Ajanta Pharma Profitability
Net profit at Ajanta Pharma Limited climbed to ₹1,056 Cr in FY2026, a 14.7% gain over the prior year.
Net margin tightened slightly, slipping to 18.8% in FY2026 from 19.4% in FY2025.
On a per-share basis, diluted EPS reached ₹84.51 for FY2026, up from ₹73.53 in the prior year.
Is Ajanta Pharma Undervalued
Under the P/E Ratio methodology, the calculated intrinsic value works out to ₹2,938.
Ajanta Pharma Limited shares are currently trading at ₹3,421.40.
Craytheon also calculates intrinsic value using the EPS Growth and DCF models. The detailed analysis includes the full breakdown, along with the assumptions behind each figure.
| Model | Est. Fair Value | vs. Current Price |
|---|---|---|
| P/E Ratio | ₹2,938 | 14.1% downside to fair value |
| EPS Growth | Upgrade | Upgrade |
| DCF | Upgrade | Upgrade |
See all valuation models for Ajanta Pharma Limited with detailed assumptions →
Ajanta Pharma Shareholding Pattern
Promoter ownership remains steady at 66.2%, with no change recorded over recent quarters.
Foreign institutional investors have pared their stake to 8.3%, down from 8.9% in the year-ago quarter.
Domestic institutional investors have built their position to 18.4% as of March 2026, up from 17.5% a year earlier.
| Quarter | Promoter | FII | DII | Public |
|---|---|---|---|---|
| Mar 2026 | 66.2% | 8.3% | 18.4% | 7.1% |
| Dec 2025 | 66.2% | 8.0% | 18.6% | 7.2% |
| Sep 2025 | 66.2% | 8.5% | 17.9% | 7.3% |
| Jun 2025 | 66.3% | 8.9% | 17.5% | 7.4% |
Track quarterly shareholding changes for Ajanta Pharma Limited →
Ajanta Pharma Balance Sheet
Proportional view as of 13 Jul 2026. Hover blocks for details.
Assets
Liabilities & Equity
FY2026 total assets: ₹61.55B (up 22.7% YoY from ₹50.15B).
Top categories: Property, Plant & Equipment (32.2%), Receivables (30.1%), Inventories (15.2%).
Of the ₹61.55B in liabilities and equity, 73.6% is shareholder equity, 4.2% is interest-bearing debt, and 22.2% is operating liabilities. Over the year, debt is up 448.7% and equity is up 19.4%.
Balance sheet composition — FY 2026
| Category | Value |
|---|---|
| Cash & ST Investments | 6.63B |
| Receivables | 18.54B |
| Inventories | 9.39B |
| Property, Plant & Equipment | 19.84B |
| Investments | 285.00M |
| Intangibles & Goodwill | 415.80M |
| Other Assets | 6.45B |
| Category | Value |
|---|---|
| Equity | 45.27B |
| Short-term Debt | 2.21B |
| Long-term Debt | 394.20M |
| Trade Payables | 5.44B |
| Other Liabilities | 8.23B |
Ajanta Pharma Investment Snapshot
Pulling together the key numbers on Ajanta Pharma Limited, the picture is fairly clear for investors evaluating this pharmaceuticals stock.
FY2026 revenue reached ₹5,625 Cr, an 18.6% increase year-over-year.
Revenue has compounded at 12.5% per year over the past 10 years.
Profitability is solid, with a net margin of 18.8% and net income of ₹1,056 Cr.
The P/E Ratio model implies 14.1% downside to fair value from the current price. The remaining two models are worth cross-checking before drawing a conclusion — sign up to see the full analysis.
Unlock Full Analysis
See the full picture — Craytheon tracks 10 years of financial data with interactive charts, growth trends, and three valuation models for Ajanta Pharma Limited.